Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer
Subjects
More information
Scope and Contents
Contents
The anti-α4β7 integrin antibody vedolizumab (VDZ) is successfully used for the treatment of inflammatory bowel diseases. However, only a subgroup of patients respond to therapy. VDZ is administered at a fixed dose, leading to a wide range of serum concentrations in patients. Previous work from our group showed a dose-dependent preferential binding...
Alternative Titles
Full title
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9236604
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9236604
Other Identifiers
ISSN
2155-384X
E-ISSN
2155-384X
DOI
10.14309/ctg.0000000000000494
